CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) Plunged 13.41% to Close at 90.920 HKD
Newtimespace News, as of the close on May 15, CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) closed at 90.920 HKD, down 13.41%. The ETF opened at 103.800 HKD, with a high of 104.000 HKD and a low of 83.760 HKD. The latest trading volume was 114 million units, with a total turnover of 10.461 billion HKD. The asset size is approximately 56.8 billion HKD.
CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) is the world's leveraged exchange-traded product tracking South Korea's SK Hynix, issued by CSOP Asset Management Limited. The product primarily employs a swap-based synthetic replication strategy, aiming to provide investors with investment performance that, before fees and expenses, seeks to deliver twice (2x) the daily performance of SK Hynix's ordinary shares. It assists investors in capturing the growth potential of this global memory leader in the AI semiconductor market during Asian trading hours.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CHI MER LAND (00978.HK): JV bid of HKD 1.03 billion for Hung Shui Kiu land accepted, constituting discloseable transaction under alternative size test
- TST PROPERTIES & SINO LAND (00247.HK/00083.HK): Consortium bid of HKD 1.03 billion for Hung Shui Kiu land accepted, JVs established for acquisition and development
- BANK OF CHINA (03988.HK): Completes issuance of RMB 20 billion write-down perpetual capital bonds at coupon rate of 1.86%
- CF PHARMTECH (02652.HK): ICF001 expands indications after implied approval from NMPA, covering four indications including pulmonary fibrosis
- TAI SANG LAND(00089.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 48.32 million, turned profitable from a loss YoY